ASTH (Astrana Health) 1-Year Sharpe Ratio: 1.17 (As of Jul. 06, 2026)


ASTH Astrana Health Inc ASTH
87 GF Score
Price $49.17
GF Value $82.75
Valuation Significantly Undervalued
! 8 Warning Signs
View Full Analysis

What is Astrana Health 1-Year Sharpe Ratio?

Astrana Health ASTH -1.26% 87 1-Year Sharpe Ratio is 1.17 as of Jul. 06, 2026. GuruFocus rates ASTH with a GF Score™ of 87/100 and a GF Value™ of $82.75 (Significantly Undervalued). The stock has 8 warning signs investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-07-06), Astrana Health's 1-Year Sharpe Ratio is 1.17.

Astrana Health  (NAS:ASTH) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Astrana Health 1-Year Sharpe Ratio Related Terms

ASTH vs SGRY, SEM, MD: 1-Year Sharpe Ratio Comparison

For the Medical Care Facilities subindustry, Astrana Health's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Astrana Health 1-Year Sharpe Ratio vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Astrana Health's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Astrana Health's 1-Year Sharpe Ratio falls into.


ASTH
87GF Score
Astrana Health Inc ASTH
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Astrana Health 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of 1.17 mean?
Astrana Health (ASTH) has a 1-Year Sharpe Ratio of 1.17 as of Jul. 06, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Astrana Health and its competitors.
Is Astrana Health's 1-Year Sharpe Ratio too high?
Astrana Health's current 1-Year Sharpe Ratio is 1.17. Overall, Astrana Health has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Astrana Health's 1-Year Sharpe Ratio compare to SGRY and SEM?
Astrana Health's 1-Year Sharpe Ratio of 1.17 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Healthcare Providers & Services company?
A good 1-Year Sharpe Ratio depends on the Healthcare Providers & Services industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Astrana Health and its competitors. Astrana Health's current 1-Year Sharpe Ratio is 1.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astrana Health stock overvalued right now?
Based on GuruFocus' analysis, Astrana Health (ASTH) is currently considered Significantly Undervalued. The stock's GF Value™ is $82.75, compared to a current price of $49.17 — trading 40.6% below its estimated fair value. The current 1-Year Sharpe Ratio is 1.17. Astrana Health's overall GF Score™ is 87/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Astrana Health (ASTH), the current 1-Year Sharpe Ratio is 1.17 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Astrana Health (ASTH) Overvalued in 2026?

Based on GuruFocus' analysis, Astrana Health stock appears to be undervalued. The current stock price of $49.17 is trading 40.6% below its estimated GF Value™ of $82.75. GuruFocus considers Astrana Health to be Significantly Undervalued.

Key valuation signals for ASTH:

  • 1-Year Sharpe Ratio: 1.17
  • GF Value™: $82.75 vs. price of $49.17 (40.6% below fair value)
  • GF Score™: 87/100 with 8 warning signs

No single metric tells the full story. See the ASTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Astrana Health Business Description

Other Exchanges 3AM:Germany
Address 1668 South Garfield Avenue, 2nd Floor, Alhambra, CA, USA, 91801
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.
87GF Score

Get the complete analysis for ASTH

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$49.17
Price
$82.75
GF Value